Jeanmarie Guenot’s Business and Medical Expertise in the Development of Innovative Cancer Therapeutics

 

 

Jeanmarie Guenot is a Ph.D. and MBA holder with more than 20 years of professionalism in the medical and biotechnology industries. Her experience is a gain from working with various labels of companies in both the private and public sectors. Currently, according to her website, Jeanmarie is specialized in ophthalmology and founded SKS Ocular to offer services in ophthalmic incubation.

SKS Ocular provides services in dry AMD, ocular drug administration, glaucoma therapy, ocular inflammation and macular degeneration. Guenot has expertise in project management, venture capital, corporate and commercial growth, and business development which aid her in working for SKS Ocular as an operating officer. Jeanmarie Guenot began her business inclined career working for Atlas Venture as the manager of investments, and life sciences firms. Her scientific career began with her recruitment at Hoffman La-Roche as a principal researcher developing and treatment for metabolic illnesses, autoimmune ailments, inflammation, and oncology.

 

Jeanmarie is a leading participator in medicinal and physical chemistry. She has trained extensively to acquire skill sets useful in quantum mechanics, molecular dynamics with semi-empirical methodologies, protein structure prediction, drug designing, and NMR and X-Ray upgrading. Presently, Jeanmarie Guenot works for Amphivena Therapeutics as the president and chief executive officer, according to her bio page on the website.

Amphivena incorporation develops progressive antibody therapeutics that are bifunctional, to treat hematologic illnesses. The firm is located in San Francisco, California and has developed cancer treatments such as AMV-564 and CD33/CD3 for leukemia treatment. In 2015, Jeanmarie Guenot stated that CD33/CD3 gained success as T-Cell redirecting bispecific with the direction of Roland B. Walter and John Dipersio. She added to say that Amphivena was set to choose a candidate for the drug’s clinical development and launch of a much better drug, the AMC-564.

 

In 2016, Amphivena announced the acceptance of the IND application procedure to test the trial of AMV564 clinically. Guenot stated that the preclinical program demonstrated a remarkable cytotoxic process in AML candidates and animal samples. She revealed that in both cases, the results were both selective and potent, hence indicating a possibility for robust therapy responses. AMV564 is an antibody that uses T-Cells to eliminate cancer cells. Jeanmarie Guenot expressed the firm’s enthusiasm in ascertaining the drug as a trustable cancer therapy treatment.

Stephen Murray: A Truly Good Guy

Stephen Murray’s accomplishments in the investing world are well-known. Quite frankly, they speak for themselves, as does his master’s degree in addition to his bachelor’s degree. However, those are great and show what type of work ethic he had and how he handled his business.

The thing that often gets overlooked and shouldn’t with Stephen Murray was the fact that he was a great philanthropist. To me, that is the true measure of a man. It is a harsh reality, but we live in a selfish world, where most people are only interested in themselves and how many things they can obtain. It is never enough.

For Stephen Murray CCMP Captial, it was never enough in terms of giving back. He was the opposite. He was the kind of person that would give you the shirt off his back. Yes, he was a private equity investor and the president and chief executive officer of CCMP Capital.

He did a lot of good there. He made great investments, good moves, and always had his pulse on the market. He knew when to stand still, when to act, and when to react. It is rare to have that kind of intuition inside of you. However, Stephen learned that from his college experience and life experience.

In the end, I’ll always remember Stephen Murray for all the good he did and all the people he helped out. Honestly, I think that is how he would want to be remembered as well. While he never did it to get attention, praise, or anything of that sort. He wanted it to be a reminder to others that you can give back and it is a good thing to give back. Not everyone is born with certain things. Learn more about Stephen Murray CCMP Capital: http://xrepublic.net/2014/09/11/stephen-murray-the-great-investor-and-deal-maker-for-ccmp-capital/

Not everything is able to obtain items they need to survive. Because of this, you have to look out for them, take care of them, and give as much as you can.

When you think of the lives that Stephen Murray has changed and impacted, it is many. These are families that are forever grateful for all he has done.

They will mourn his loss, just like the rest of us, but it is important to remember what he has done. Stephen wouldn’t want us to sit around and be sad. He would want us to celebrate him and remember him for the wonderful human being that he was, every day, 24/7. That’s how I will remember him, for sure.